The energy at DIA Europe 2026 annual meeting was palpable.
1500+ life sciences professionals from across 50 countries came together. The gathering was a mix of 40+ regulators, 15+ HTA bodies, 20+ patient organisations, alongside pharma leaders, startups, and investors, all under one roof.
That diversity is rare. And it’s exactly what made conversations sharper, more grounded and focused.
From the very start, we saw one question dominate the discussions this year:
Can Europe keep up with the speed of global healthcare innovation or risk falling behind?
During the Opening Plenary, Max Wegner of Bayer AG delivered a message that stuck with us. Europe, he said, stands at a crossroads.
Will Europe become an “industrial museum” of past achievements, or will it rebuild itself as the engine for future healthcare breakthroughs?
And that question followed every panel, every debate, and every hallway conversation across three packed days from March 24–26.
Speed, regulation, and Europe’s balancing act
The opening sessions brought together a powerful mix of policymakers, patient advocates, and industry leaders.
Rainer Becker from the European Commission unpacked the policy landscape shaping Europe’s healthcare future, while Jan Geissler of Patvocates grounded the discussion in patient realities.
Both stood on the same core theme: Europe has the talent, science, and infrastructure, but it’s losing out on speed.
It was Max Wegner, SVP Head of Regulatory Affairs at Bayer AG, who cut to the chase. Europe has the assets for global leadership, he acknowledged, but innovation cycles are shrinking, and global competition is accelerating.
He highlighted two policy developments:
1. The new pharma legislation
The proposed reform of Europe’s pharmaceutical framework is one of the biggest in decades. It aims to:
- Shorten approval timelines
- Improve access to medicines across member states
- Incentivise innovation, especially in unmet medical needs
- Rebalance regulatory protections (like data exclusivity) with faster market access
2. The EU Biotech Act (proposed)
Still evolving, the Biotech Act is designed to:
- Strengthen biotech R&D and manufacturing within Europe
- Reduce dependency on external markets
- Streamline funding, approvals, and cross-border collaboration
- Position Europe as a serious competitor to the US and China in biotech innovation
He said, regulation is the double-edged sword, both a strength and a bottleneck.
And that’s where we observed the conversatio getting more nuanced.
Europe is globally respected for its high regulatory standards, especially in areas like:
- Data privacy (General Data Protection Regulation)
- Clinical safety and trial governance
- AI and digital health compliance
- Patient rights and ethical frameworks
In healthtech, this creates trust, arguably Europe’s biggest advantage.
But it also creates friction. Startups and innovators repeatedly pointed out that:
- Approval pathways can be slow and fragmented
- Compliance requirements can be resource-heavy, especially for early-stage companies
- Different member states interpret rules differently, adding complexity
So while regulation builds credibility, it can also delay innovation and push investment toward faster markets. Execution speed, not just policy direction, will decide outcomes.
That tension, between trust and speed, was at the heart of nearly every discussion. Across 80+ sessions and 10 thematic tracks, this question kept resurfacing:
Can Europe turn regulation into a competitive advantage, or will it continue to slow innovation down?
From patient-centric to patient-partnered
Another significant shift we saw emerge throughout the event was: The role of patients is evolving fast.
Speakers like François Houyez and Tomasz Grybek of EURORDIS emphasised that,
Patients are no longer just participants. They’re partners.
They should not be treated as data sources. Instead, they must be data partners, sitting at the table in
- Co-creating research
- Contributing to data interpretation
- Sharing accountability in outcomes
Experts focused on regulatory sandboxes as they’re flexible frameworks that allow innovation while maintaining safety and ethics.
You can’t build the future of healthcare for patients without building it with them.
DIA Europe 2026 Inspire Awards: Spotlight on changemakers
The event also celebrated individuals and organisations shaping the future of life sciences. The 2026 Inspire Award winners went to:
Excellence in Service Award: James Whitehead (Egetis Therapeutics), Aimad Torqui (MEB) and Monique Al (CCMO), for unwavering dedication to regulatory and research integrity.
Distinguished Career Award: Karl Christian Broich (BfArM), for the legacy of leadership shaping drug and medical device safety.
Leader of Tomorrow Award: Beyza Hayroviç (Novartis), for bold, brilliant, and breaking barriers.
Outstanding Contribution to Health Award: EUPATI, The European Patients’ Academy on Therapeutic Innovation
The LIFT programme and healthtech innovation
Healthtech and biotech innovation were front and centre, particularly in the newly launched LIFT Start-Up Accelerator Programme. This two-day pre-conference event was designed to bridge the gap between early-stage teams and the complex European regulatory landscape.
The programme provided a focused environment where start-ups engaged directly with venture capitalists, regulators, and HTA bodies.
The Pitch Competition highlights
The Start-Up Pitch Competition was where selected innovators presented their ideas to a panel of investors and pharma leaders, receiving real-time feedback and gaining visibility.
The winner: Enrique Hernández Jiménez from Loop Diagnostics (Loop Dx)
Barcelona-based biotech startup, Loop Dx, impressed judges with SeptiLoop®. An innovative in vitro diagnostic designed to detect immune dysregulation linked to sepsis at its earliest stages.
Other finalists:
Ilinka Stanciu from CC Diagnostics
Taking second place, CC Diagnostics is a Dutch health-tech startup focused on improving early detection of cervical cancer through molecular diagnostics.
Christina Port from 2NA FISH
In third place, 2NA FISH is a molecular diagnostics company specialising in detecting infections faster and more precisely.
The data behind the competitiveness debate
The discussions on competitiveness were grounded in new data. Nathalie Moll highlighted that competitiveness is about speed.
Europe leads in research and manufacturing, but lags in regulatory pace. The result is investment following faster pathways elsewhere.
The opportunity, however, is massive:
- 200+ accelerated approvals in the next decade.
- 100 of them potentially originating in Europe
But only if the system moves faster, starting now. For regulators and industry alike, speed today means access and growth tomorrow.
Leaders of Tomorrow: Building the next generation
One of the more unique aspects of DIA Europe was the Leaders of Tomorrow programme, a dedicated, full-day experience designed to:
- Connect young professionals with senior industry leaders
- Go beyond technical knowledge into leadership, communication, and career journeys
- Provide real-world insights into navigating the life sciences ecosystem
It acted as a bridge between emerging talent and the people shaping the industry today. In a sector facing talent gaps and rapid transformation, this focus on human capital felt especially relevant.
Wrapping up
Three days. Dozens of sessions. Hundreds of conversations. And one clear conclusion:
Innovation knows no borders, but investment does.
Europe’s future in life sciences won’t be defined by how strong its science is. It will be defined by how fast its systems can move.
Unless systems move faster on regulation, approvals, and collaboration, investment will continue to flow elsewhere.
-By Alkama Sohail and the AHT Team
